Abstract
In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.
| Original language | English |
|---|---|
| Pages (from-to) | 396-402 |
| Number of pages | 7 |
| Journal | European Journal of Cancer |
| Volume | 42 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2006 |
Fingerprint
Keywords
- Complications
- Epidemiology
- Multiple myeloma
- Survival
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Changes in multiple myeloma epidemiology in the last thirty years : A single centre experience. / Zappasodi, Patrizia; Corso, Alessandro; Klersy, Catherine; Pica, Gianmatteo; Mangiacavalli, Silvia; Varettoni, Marzia; Rusconi, Chiara; Pascutto, Cristiana; Lazzarino, Mario.
In: European Journal of Cancer, Vol. 42, No. 3, 02.2006, p. 396-402.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changes in multiple myeloma epidemiology in the last thirty years
T2 - A single centre experience
AU - Zappasodi, Patrizia
AU - Corso, Alessandro
AU - Klersy, Catherine
AU - Pica, Gianmatteo
AU - Mangiacavalli, Silvia
AU - Varettoni, Marzia
AU - Rusconi, Chiara
AU - Pascutto, Cristiana
AU - Lazzarino, Mario
PY - 2006/2
Y1 - 2006/2
N2 - In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.
AB - In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.
KW - Complications
KW - Epidemiology
KW - Multiple myeloma
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=31144451768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31144451768&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2005.09.031
DO - 10.1016/j.ejca.2005.09.031
M3 - Article
C2 - 16403623
AN - SCOPUS:31144451768
VL - 42
SP - 396
EP - 402
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 3
ER -